Bovine transfer factor: effect on bovine and rabbit coccidiosis

Physiologic, health, and performance responses of beef steers supplemented with an immunomodulatory feed ingredient during feedlot receiving

One hundred eight Angus × Hereford steers, originating from 7 cow-calf were obtained from an auction yard on d -2 and transported by road (800 km; 12 h) to an experimental feedlot facility. Upon arrival on d -1, shrunk BW was recorded and steers were grouped with free-choice access to grass hay, mineral supplement, and water. On d 0, steers were ranked by source and shrunk BW and assigned to 1 of 18 pens (6 steers/pen). Pens were allocated to 1) no immunomodulatory ingredient supplementation during feedlot receiving (CON), 2) supplementation with OmniGen-AF (OMN; 22 g/steer daily, as-fed basis; Phibro Animal Health Corp., Teaneck, NJ) from d 0 to 30, or 3) 2 oral capsules of Stocker Immune Primer on d 0 + 15 g/steer daily (as-fed basis) of Stocker Preconditioned Premix (Ramaekers Nutrition, Santa Cruz, CA) from d 7 to 30 (IPF). From d 0 to 80, steers had free-choice access to grass hay and water and received a corn-based concentrate. Feed DMI was recorded from each pen, and steers were assessed for bovine respiratory disease (BRD) signs daily. Steers were vaccinated against BRD pathogens on d 0 and 21. Final shrunk BW was recorded on d 81, and blood samples were collected on d 0, 3, 7, 10, 14, 21, 31, 42, 56, and 73. Steer ADG and final BW were greater ( ≤ 0.05) in CON steers than in OMN and IPF steers (1.23, 0.76, and 1.06 kg/d [SEM 0.06], respectively, and 320, 282, and 307 kg [SEM 4], respectively) and ( < 0.01) in IPF steers than in OMN steers. No treatment effects were detected ( ≥ 0.76) for BRD incidence (66 ± 4%) and DMI, whereas G:F was greater ( < 0.01) in OMN steers than in CON steers. Mean plasma cortisol concentration was greater ( = 0.01) in CON steers than in OMN and IPF steers. Plasma haptoglobin concentrations tended ( = 0.10) to be greater in CON steers than in IPF steers on d 3, were greater ( = 0.04) in IPF steers than in CON steers on d 7, and tended ( = 0.10) to be less in OMN steers than in IPF and CON steers on d 21. Blood mRNA expression of was greater ( ≤ 0.05) in OMN and IPF steers than in CON steers on d 3 and in OMN steers than in CON and IPF steers on d 14. Blood mRNA expression of was greater ( ≤ 0.05) in OMN and IPF steers than in CON steers on d 10. Plasma IGF-I concentrations, serum antibody titers to BRD pathogens, and blood mRNA expression of , , , and did not differ ( ≥ 0.21) among treatments. Collectively, the immunomodulatory feed ingredients evaluated herein impacted adrenocortical and innate immune responses but failed to mitigate BRD incidence and improve performance of receiving cattle.

Inability of oral bovine transfer factor to eradicate cryptosporidial infection in a patient with congenital dysgammaglobulinemia

A 31-year-old man with dysgammaglobulinemia Type I (deficient IgG, IgA, and elevated IgM) and persistent cryptosporidiosis was treated over a 13-week period with oral bovine transfer factor from calves immunized with cryptosporidia. Spiramycin was added toward the end of the treatment period. This patient failed to show clinical response although there was a decrease in the stool oocyst count from the value just prior to therapy. Bovine transfer factor alone and in combination with spiramycin failed to eradicate the infection in this man with well-documented stable cryptosporidiosis.

Treatment of cryptosporidiosis with oral bovine transfer factor

Cryptosporidia are intestinal protozoans long known to cause diarrhea in humans, especially those with acquired immune deficiency syndrome (AIDS). When transfer factor prepared from calves which possessed delayed-type hypersensitivity to Eimeria bovis was given to nonimmune calves and mice it conferred protection against clinical infection (coccidiosis). Recent studies with oral bovine transfer factor have shown that it can confer cell-mediated immunity to humans. Based on these findings we decided to treat eight AIDS patients suffering from Cryptosporidium-associated diarrhea with transfer factor prepared from calves immune to Cryptosporidium. Prior to treatment with transfer factor, three patients had been treated with spiramycin, one patient with alpha-difluoromethylornithine (DFMO), and one patient with furazolidone for greater than 1 month without clinical or laboratory improvement. Following administration of transfer factor, five or eight patients exhibited a decrease in the number of bowel movements and the development of formed stools. Cryptosporidium was eradicated from the stools of four patients but two of these patients subsequently relapsed and one patient continued to have diarrhea despite the absence of Cryptosporidium in the stool. One patient has been free of diarrhea and Cryptosporidium for 2 years after discontinuation of transfer factor therapy.

An animal model for evaluation of antigen-specific dialyzable leukocyte extracts therapy of osteosarcoma

The effects of human osteosarcoma (OS)-specific dialyzable leukocyte extracts (DLE) in hamsters bearing human OS were investigated. The DLE used in this investigation was prepared from rabbits immunized with human osteosarcoma-associated antigens (DLE-OSAA). Tuberculin (DLE-PPD) and control DLE were prepared from rabbits injected with tuberculin or 0.85% NaCl (DLE-NaCl). DLE was administered subcutaneously into inbred hamsters (each injection contained DLE derived from 10(7) rabbit leukocytes). Four groups of animals were studied: group 1, amputation alone; group 2, amputation plus DLE-OSAA; group 3, amputation plus DLE-PPD; group 4, amputation plus DLE-NaCl. Of the DLE-OSAA-treated animals (group 2), 60% were still alive at 300 days postamputation; whereas in animals in groups 1, 3, and 4, all died within 90 days postamputation. In separate experiments, we found that 100% of the animals in groups 1, 3, and 4 developed pulmonary metastases within 30-60 days postamputation, whereas only 20% of the animals in group 2 developed metastases at the same time; indeed 40% of the DLE-OSAA-treated animals were free of metastases in 240-300 days postamputation. Both the leukocyte adherence inhibition assay (LAI) and lymphocyte DNA synthesis assay (LDS) were used to monitor the transfer of antigen-specific cell-mediated immunity in each group of tumor-bearing hamsters. All surviving hamsters in group 2 had high LAI and LDS activity. Our results suggest that DLE-OSAA is effective in preventing pulmonary metastases and death of OS-bearing hamsters (after amputation) as compared with amputation alone, amputation plus DLE-NaCl, and amputation plus DLE-PPD, and that its effect is via an antigen-specific mechanism.

Transfer of osteosarcoma-specific cell-mediated immunity in hamsters by rabbit dialyzable leukocyte extracts

We have investigated the transfer of specific cell-mediated immunity (CMI) to osteosarcoma-associated antigens (OSAA) to hamsters with dialyzable leukocyte extracts (DLE) from OSAA-immunized rabbits. The transfer of specific CMI was determined by leukocyte adherence inhibition (LAI) assay and skin testing. DLE was prepared from rabbits immunized with OSAA, purified protein derivative (PPD), or fibrosarcoma cell plasma membrane preparation (FSM). Control DLE was prepared from rabbits injected with 0.85% NaCl. Significant leukocyte adherence inhibition was observed with leukocytes from hamsters that had received OSAA-specific, PPD-specific, and FSM-specific rabbit DLE, when OSAA, PPD, and FSM were used as antigens, respectively. Similarly, significant ear swelling after injection of OSAA, PPD, or FSM was observed only in hamsters that had received DLE from rabbits immunized with OSAA, PPD, or FSM, respectively. These results suggest that CMI specific for OSAA, PPD, or FSM can be transferred to normal hamsters by DLE from immunized rabbits.

Evidence of cell mediated immune response in infection with Eimeria bareillyi in buffaloes

Delayed dermal hypersensitivity and leucocyte migrations were measured in buffalo calves experimentally inoculated with Eimeria bareillyi. Dermal hypersensitivity, characterized by increased thickness and local inflammation, was observed in calves inoculated intradermally with E. bareillyi antigen on Days 21 and 28 after infection. The highest inhibition of leucocyte migration was observed in infected buffalo calves on Days 21 and 28 post-infection.

Coccidiosis: rapid depletion of circulating lymphocytes after challenge of immune chickens with parasite antigens

Characteristic changes in the numbers of peripheral blood leukocytes occurred after specific challenge of chickens immunized by infection with the intracellular intestinal coccidian parasite Eimeria maxima. Within minutes of enteric or intravenous challenge with viable parasites or with soluble parasite antigen, the numbers of circulating lymphocytes and, to a lesser extent, of heterophils were reduced. This was followed by a period of leukocytosis, the main cellular constituents of which were heterophils and lymphocytes. Indirect fluorescent staining with antisera to T- or B-lymphocytes showed the depletion in lymphocytes to be accounted for mainly by a reduction in the number of T-cells. The leukopenia after oral challenge, found in immunized birds, could be transferred to normal birds by the intravenous injection of serum, plasma, extracts of leukocytes, or suspensions of viable spleen cells.

Adoptive transfer of delayed hypersensitivity and protective immunity to Eimeria tenella with chicken-derived transfer factor

Delayed hypersensitivity (DH) and protective immunity were transferred to nonimmune 4- and 10-week-old broiler chickens with transfer factor (TF) prepared from splenic leukocytes of chickens immunized with CocciVac D. Only chickens injected with the immune TF showed DH by wattle reaction to oocyst antigen and protective immunity to Eimeria tenella challenge infection. Chickens given a single injection of TF 5 days before challenge infection exhibited a significant (P less than .05) DH response at the time of infection. Immune TF preparations were active at concentrations of 100, 200, or 400 mg. Neither DH nor protective immunity was transferred to chickens injected with the TF-diluent control or nonimmune TF. The nonimmune TF was prepared from chickens kept free of coccidial infection. These findings indicated that TF prophylaxis produced beneficial results in nonimmune chickens by conferring some protection against challenge with E. tenella. The effects of TF on T-lymphocyte mediated protective immunity to coccidia in chickens are discussed.

Adoptive transfer of delayed wattle reactivity in chickens with a dialyzable leukocyte extract containing transfer factor

Delayed wattle reactions (DWR) to tuberculin, diphtheria toxoid (DT), and keyhole limpet hemocyanin (KLH) were transferred to chickens with dialyzable leukocyte extracts (DLE) prepared from splenic leukocytes of chickens sensitized and reactive by DWR to the tuberculin, DT, or KLH. A DLE prepared from chickens unsensitized and unreactive to tuberculin by DWR failed to transfer DWR to tuberculin in recipients. Only chickens injected with DLE from tuberculin sensitized and reactive chickens exhibited significant (P less than .01) DWR to tuberculin. Chickens that received DLE prepared from DT sensitized and reactive chickens exhibited significant (P less than .01) DWR to DT but not to KLH. Further, DWR to both DT and KLH was transferred with DLE prepared from chickens sensitized to both antigens. Adoptive transfer of DWR to KLH in comparison to DT was more successful. Finally, the serial transfer of DWR to KLH (P less than .05) but not to DT (P greater than .05) was accomplished using DLE prepared from chickens that previously were recipients of DLE prepared from chickens sensitized to KLH and DT. Results indicate that DLE prepared from chickens contain transfer factor (TF) responsible for adoptive transfer of DWR to tuberculin, DT, and KLH.

Immunopotentiation against internal parasites

The economic importance of livestock losses attributed to internal parasites has led to the need of developing and successfully employing effective antiparasitic vaccines. An increasingly important strategy in the development of more effective vaccines is the preparation and use of immunopotentiators or adjuvants. Immunopotentiators or adjuvants have been used effectively in combination with antigen(s) or alone to protect animals against internal parasites. The use of immunopotentiators for specific and nonspecific stimulation of protective immunity against internal parasites is reviewed.

Transfer of Salmonella resistance and delayed hypersensitivity with murine-derived transfer factor

Protective host immunity and delayed hypersensitivity were transferred to nonimmune ICR and C3H/HeJ mice with transfer factor prepared from the splenic lymphocytes of ICR Swiss mice immune to Salmonella typhimurium. Only mice injected with the "immune" dialysate exhibited significant footpad swelling (P less than 0.01) to a spent medium antigen of S. typhimurium, but not Listeria monocytogenes. Host survival to a lethal Salmonella challenge infection was seen only in transfer factor-injected mice. Also, these challenged animals had fewer numbers of bacteria present in their spleens (P less than 0.01) than did challenged mice previously injected with either control dialysates or commercial endotoxin. Neither the Salmonella antigens nor endotoxin present in the sterile transfer factor preparation was responsible for the transfer of host protection and delayed hypersensitivity, since none of the control dialysates resulted in any positive responses when injected into either the ICR Swiss or endotoxin-resistant C3H/HeJ mice.

Investigations of transfer factor activity in resistance to Trichostrongylus colubriformis infections in guinea-pigs

Resistance to challenge infection with Trichostrongylus colubriformis was studied in an outbred strain of guinea-pigs. Resistance was conferred by previous infections of 50 or 100 infective larvae and by intraperitoneal, intramuscular and subcutaneous administration of dialysed transfer factor prepared from guniea-pigs infected with T. colubriformis, by intraperitoneal administration of transfer factor prepared from the blood of sheep infected with T. colubriformis and on one of three occasions using transfer factor prepared from guinea-pigs which had not been infected with T. colubriformis. No significant resistance was transferred by administration of antigen prepared from adult T. colubriformis, or by non-dialysed transfer factor, or by dialysed transfer factor prepared from T. colubriformis-infected guinea-pig tissue which had been stored for several months at - 20 degrees C.

Chicken coccidiosis: correlation between resistance and delayed hypersensitivity

Broiler chickens were immunized with viable oocysts of Eimeria necatrix, E. tenella, or with a commercially prepared vaccine (CocciVac D) containing oocysts from eight chicken Eimeria species. Before challenge with oocysts of E. necatrix or E. tenella, delayed hypersensitivity (DH) reactions to particulate-oocyst antigen extracts of E. nectrix, E. maxima, and E. tenella were demonstrated in the previously immunized broilers. Broilers immunized, tested for DH, and challenged showed good corrrelation between DH reactions and resistance in each homologous trial. Birds immunized with CocciVac D also gave good correlation between DH reactions to E. maxima, E. necatrix, or E. tenella antigens and resistance when challenged with E. necatrix or E. tenella oocysts. Oocyst antigens from E. maxima, E. necatrix, or E. tenella were cross reactive for DH, indicating some antigen sharing among species of chicken coccidia. A few broilers immunized with chicken coccidia showed DH to an oocyst antigen from E. bovis, a cattle pathogen. Results show that DH to oocyst antigens can predict resistance to coccidiosis.

Transfer factor

The understanding of passive transfer of cell mediated-immune responses with transfer factor and other cell free materials has progressed to the point that investigators are seeking the chemical identity of the molecule(s) that are responsible for these effects and are working on their mechanisms of action. In addition, clinical trials are underway that should clarify the potential for use of transfer factor in treatment of infections, neoplastic and autoimmune diseases. This chapter will critically review the past and current data concerning the components of transfer factor and their effects on immunologic and inflammatory reactions. Some of the recently developed animal models will be described and evaluated, and the clinical studies that have provided conclusive data regarding efficacy will be reviewed.